Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT)

2seventy bio (NASDAQ:TSVT)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

2seventy bio Stock Up 7.0 %

Shares of NASDAQ:TSVT opened at $2.61 on Friday. The company’s 50-day moving average price is $3.28 and its 200 day moving average price is $4.15. The company has a market cap of $134.65 million, a PE ratio of -1.40 and a beta of 1.76. 2seventy bio has a fifty-two week low of $2.35 and a fifty-two week high of $6.40.

Hedge Funds Weigh In On 2seventy bio

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in 2seventy bio by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after acquiring an additional 13,144 shares during the period. State Street Corp grew its stake in shares of 2seventy bio by 1.5% in the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock worth $4,997,000 after purchasing an additional 15,638 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of 2seventy bio by 50.4% during the second quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after purchasing an additional 223,408 shares during the period. Western Standard LLC bought a new stake in shares of 2seventy bio during the third quarter valued at about $1,350,000. Finally, Wellington Management Group LLP lifted its holdings in 2seventy bio by 9.0% in the third quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock worth $1,237,000 after purchasing an additional 21,673 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.